Fulcrum Therapeutics, Inc.

Good morning and welcome to the Fulcrum Therapeutics first quarter 2023 financial results and business update conference call. Currently, all participants are in the listen only mode. This call is being webcast live on the investor section of Fulcrum's website at www.fulcrumtx.com and is being recorded. For opening remarks, I would like to introduce Chris Calabrese. Please go ahead.

Thank you and good morning.

Welcome to the Fulcrum Therapeutics First Quarter 2023 Financial Results and Business Update Conference Call. Please be reminded that remarks made during this call may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These may include statements about the company's future expectations and plans, including the clinical hold of FTX 6058, clinical development timelines, and financial projections. While these forward-looking statements represent Fulcrum's views as of today, this should not be relied upon as representing the company's views in the future. Fulcrum may update these statements in the future, but is not taking on an obligation to do so. Please refer to Fulcrum's most recent filings with the Securities and Exchange Commission for a discussion of certain risks and uncertainties associated with the company's business. Leading the call today will be Dr. Robert Gould, Interim Chief Executive Officer at Fulcrum, who will provide a corporate overview, discuss key pipeline updates, as well as the financials before we open the call for Q&A. And Dr. Ian Frazier, Interim Chief Medical Officer, will be able to answer questions during the Q&A portion of the call. With that, it's my pleasure to turn the call over to Robert.